NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/27/2026
Back to search
Official data from USPTO
A2 BIO
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
46
Latest update
01/28/2026
Trademark type
Combined
Nice classes
5, 40, 42
Filing date
10/14/2021
Registration date
01/27/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/27/2026
Last transaction
01/28/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
05/01/2023
First use in commerce
05/01/2023
Drawing code
3
Owner type
03
Owner location
Agoura Hills, CA
Examiner
WOO, SAMUEL M
Law office
O70
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a black square with white frame and black border containing "A2" in white text in the lower right quadrant, with the word BIO in black text appearing under the number 2 and breaking the black and white border.
Holders and representatives
Holders
A2 Biotherapeutics, Inc.
Representatives
Joi A. White CARR & FERRELL LLP
Technical classification
Nice Classes
Class 5Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Therapeutics in the nature of cellsproteins and protein complexes for the treatment and prevention of cancer; biotherapeutics for the treatment and prevention of cancer; medicines for the treatment and prevention of cancer; pharmaceutical products for the treatment and prevention of cancer; therapeutic targetsproteins or protein complexesfor the treatment and prevention of cancer; therapeutic cellstherapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer; therapeutics and cell therapies in the nature of cellsproteins and protein complexes for the treatment of cancer; engineered cell therapies in the nature of cellsproteins and protein complexes for medical purposesthe treatment and prevention of cancer; engineered cell therapy platforms consisting of modified cellscell receptorsproteins and protein complexes; cell platforms consisting of modified cellscell receptorsproteins and protein complexes for the treatment and prevention of cancer; technology platforms for developing and engineering therapeutic cellstherapeutic proteinstherapeutic antibodiestherapeutics and cellular therapies for the treatment and prevention of cancer; platform for autologous and allogeneic cell manufacturing; therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer; gene therapy productsgenetically engineered tissues for transplant purposes;
Class 40
Custom manufacturing of therapeuticsbiotherapeuticsmedicinespharmaceuticals; manufacturing of cellstherapeutics and cell therapies for the treatment and prevention of cancer; biomanufacturing for othersmanufacturing of cellstherapeutics and cell therapies for the treatment and prevention of cancer using biological cells in the manufacturing process; cell therapy manufacturing for others; autologous and allogeneic cell manufacturing for others; manufacturing services for others in the fields of therapeuticscell therapiesbiologicsmedicinepharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; custom manufacturing and engineering of biological cellscellular targetsproteinsantibodies for others for treatment and prevention of cancer;
Class 42
Medical research services; pharmaceutical and biopharmaceutical research and development services; provision of medical and scientific research information in the fields of therapeuticsbiotherapeuticsmedicinespharmaceuticals; identification and development of therapeutic targets for others for the treatment and prevention of cancer; development of therapeutics and cell therapies for treatment and prevention of cancer; research and development of therapeutics and cell therapies targeting targets lost for the treatment and prevention of cancer; biotechnology researchdevelopmenttesting and analysis for the treatment of cancer; scientific research and development services; providing scientific information relating to treatment and prevention of cancer; researchdevelopmentengineering and testing services in the fields of therapeuticscell therapiesbiologicsmedicinepharmaceuticals; medical laboratory servicestissue material processing and analysis in the field of autologous and allogeneic biologic preparations for medical use; biotechnology laboratory services; scientific and medical laboratory services; genetic engineering services;
Publications
History of USPTO decisions and trademark events.
46 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
01/27/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
01/02/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
01/02/2026
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/11/2025
SUPC
STATEMENT OF USE PROCESSING COMPLETE
11/10/2025
DPCC
DIVISIONAL PROCESSING COMPLETE
11/10/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
11/07/2025
IUAF
USE AMENDMENT FILED
05/30/2025
DRRR
DIVISIONAL REQUEST RECEIVED
05/30/2025
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
05/30/2025
EISU
TEAS STATEMENT OF USE RECEIVED
05/30/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/20/2025
EX4G
SOU EXTENSION 4 GRANTED
05/20/2025
EXT4
SOU EXTENSION 4 FILED
05/19/2025
EEXT
SOU TEAS EXTENSION RECEIVED
05/19/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/07/2024
EX3G
SOU EXTENSION 3 GRANTED
11/07/2024
EXT3
SOU EXTENSION 3 FILED
11/07/2024
EEXT
SOU TEAS EXTENSION RECEIVED
11/07/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/15/2024
EX2G
SOU EXTENSION 2 GRANTED
05/14/2024
EXT2
SOU EXTENSION 2 FILED
05/14/2024
EEXT
SOU TEAS EXTENSION RECEIVED
05/14/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/21/2023
EX1G
SOU EXTENSION 1 GRANTED
11/17/2023
EXT1
SOU EXTENSION 1 FILED
11/17/2023
EEXT
SOU TEAS EXTENSION RECEIVED
11/17/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
05/30/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/04/2023
PUBO
PUBLISHED FOR OPPOSITION
04/04/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/15/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/25/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/24/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/23/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/23/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/22/2022
GNRT
NON-FINAL ACTION E-MAILED
07/22/2022
CNRT
NON-FINAL ACTION WRITTEN
07/22/2022
DOCK
ASSIGNED TO EXAMINER
07/20/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/13/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/13/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/13/2022
MDSM
NOTICE OF DESIGN SEARCH CODE E-MAILED
11/04/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/03/2021
NWAP
NEW APPLICATION ENTERED
10/18/2021
Continuous trademark protection
Get notified about every new filing that threatens A2 BIO or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.